About: Inhibition of HBV gene expression and replication by stably expressed interferon‐α1 via adeno‐associated viral vectors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of HBV gene expression and replication by stably expressed interferon‐α1 via adeno‐associated viral vectors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhibition of HBV gene expression and replication by stably expressed interferon‐α1 via adeno‐associated viral vectors
Creator	Zheng, Bo-Jian Huang, Jian-Dong Ma, Yan He, Ming-Liang Peng, Ying Kung, Hsiang-Fu Dong, Qingming Lin, Marie Sung, Joseph Yuen, Li, Zhi Chan, Chu-Yan Chen, Yangchao Kwok, Yun Yao, Hong
Source	Medline; PMC
abstract	BACKGROUND: Interferon‐α2 (IFNα2) is routinely used for anti‐hepatitis B virus (HBV) treatment. However, the therapeutic efficiency is unsatisfactory, particularly in East Asia. Such inefficiency might be a result of the short half‐life, relatively low local concentration and strong side‐effects of interferons. Frequent and repeated injection is also a big burden for patients. In the present study, a single dose of vector‐delivered IFNα1 was tested for its anti‐HBV effects. METHODS: Adeno‐associated viral vector (AAV‐IFNα1) was generated to deliver the IFNα1 gene into hepatocytes. IFNα1, hepatitis B surface (HBsAg) and e (HBeAg) antigens were measured by enzyme‐linked immunosorbent assay and/or western blotting. The level of viral DNA was measured by quantitative real‐time polymerase chain reaction. RESULTS: AAV‐IFNα1 effectively transduced HBV‐producing cells (HepAD38) and mouse hepatocytes, where IFNα1 was expressed in a stable manner. Both intracellular and extracellular HBsAg and HBeAg were significantly reduced in vitro. In the HBV‐producing mice, the concentration of IFNα1 in the liver was eight‐fold higher than that in plasma. Compared with control groups, HBeAg/HBsAg antigen levels were reduced by more than ten‐fold from day 1–5, and dropped to an undetectable level on day 9 in the AAV‐IFNα1 group. Concurrently, the level of viral DNA decreased over 30‐fold for several weeks. CONCLUSIONS: A single dose administration of AAV‐IFNα1 viral vector displayed prolonged transgene expression and superior antiviral effects both in vitro and in vivo. Therefore, the use of AAV‐IFNα1 might be a potential alternative strategy for anti‐HBV therapy. Copyright © 2008 John Wiley & Sons, Ltd.
has issue date	2008-03-31(xsd:dateTime)
bibo:doi	10.1002/jgm.1174
bibo:pmid	18383553
has license	no-cc
sha1sum (hex)	cd031554c346aac5815e9cfa33dcb762a3a9ae91
schema:url	https://doi.org/10.1002/jgm.1174
resource representing a document's title	Inhibition of HBV gene expression and replication by stably expressed interferon‐α1 via adeno‐associated viral vectors
has PubMed Central identifier	PMC7166674
has PubMed identifier	18383553
schema:publication	J Gene Med
resource representing a document's body	covid:cd031554c346aac5815e9cfa33dcb762a3a9ae91#body_text
is schema:about of	named entity 'concentration' named entity 'local' named entity 'viral vectors' named entity 'DELIVERED' named entity 'SHORT' named entity 'LOW' named entity 'SINGLE' named entity 'MIGHT BE' named entity 'HBV' named entity 'EFFICIENCY' covid:arg/cd031554c346aac5815e9cfa33dcb762a3a9ae91 named entity 'HBV' named entity 'Background' named entity 'therapeutic' named entity 'repeated' named entity 'inefficiency' named entity 'vector' named entity 'HBV' named entity 'gene expression' named entity 'HBV' named entity 'HBeAg' named entity 'shRNA' named entity 'culture media' named entity 'liver' named entity 'transduce' named entity 'animal study' named entity 'HBeAg' named entity 'HBV' named entity 'assay' named entity 'hepatic' named entity 'transfection' named entity 'infection' named entity 'aspartate' named entity 'human gene therapy' named entity 'tail vein' named entity 'IFNα' named entity 'EGFP' named entity 'regulatory element' named entity 'clinical trials' named entity 'AAV' named entity 'AAV2' named entity 'Dulbecco's modified Eagle's medium' named entity 'therapeutic effects' named entity 'vector' named entity 'genotype' named entity 'AAV' named entity 'plasma' named entity 'rAAV' named entity 'IFN' named entity 'antiviral' named entity 'primers' named entity 'HBV' named entity 'HBV' named entity 'HCC' named entity 'liver cells' named entity 'PBS' named entity 'IFNα' named entity 'AAV' named entity 'vector' named entity 'HBsAg' named entity 'genotype' named entity 'plasma' named entity 'alanine' named entity 'HBeAg' named entity 'HBeAg' named entity 'gene therapy' named entity 'transfected'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software